Guide
503A vs 503B: the pharmacy distinction that decides your safety
Every prescribed peptide is made by a compounding pharmacy. 503B is the higher manufacturing standard — but nearly all telehealth peptide therapy runs through 503A. Here's what that actually means for what's in your vial.
Every prescribed peptide you take is made by a compounding pharmacy. Which kind of
compounding pharmacy is one of the two things that most determines whether what's in your vial is what's
on the label — and almost no provider explains the difference.
| 503A | 503B |
|---|
| What it is | Traditional compounding pharmacy | FDA-registered outsourcing facility |
| Makes drugs for | A specific patient with a prescription | Bulk, without patient-specific Rx |
| FDA inspection | State board; FDA under insanitary-conditions guidance | Routine FDA inspection |
| cGMP compliance | Not required | Required |
| Per-batch testing | Varies wildly by pharmacy | Standard |
| Who uses it | Nearly all telehealth peptide providers | Hospitals, clinics, some larger platforms |
The honest summary
503B is the higher manufacturing standard. But almost all telehealth peptide therapy runs through
503A, because 503A is what allows a patient-specific prescription. So the real question
isn't "is my provider 503A or 503B" — it's
"which 503A pharmacy, and do they publish
per-batch testing?"The question to actually ask
Ask your provider: which pharmacy fills my prescription, and can I see the batch testing for my
lot? A provider that names the pharmacy and produces per-batch third-party HPLC purity,
mass-spectrometry identity, and endotoxin results is operating at the top of this category.
FormBlends publishes this by default, which is why it posts our
highest pharmacy-sourcing score. TrimRx names Casa Pharma RX and
discloses per-batch third-party testing. Most providers do neither.
Why the 503B route mostly isn't available
Compounded GLP-1s were widely produced during the FDA shortage period. The semaglutide shortage was
declared resolved in February 2025 and tirzepatide in December 2024 — which narrows the legal
authority for mass-scale compounding and pushes the market back toward patient-specific 503A
prescriptions. That's the regulatory backdrop to the FDA's 2025–2026 enforcement wave.
See the warning-letter tracker →Check your label when it arrives
Verify the pharmacy name, the active ingredient, the concentration, and the beyond-use date. If the
pharmacy isn't named on the label, that itself is information.
FAQ
Is 503A or 503B safer?
503B facilities are FDA-registered, cGMP-compliant, and routinely inspected — a higher manufacturing standard. But 503A is what permits a patient-specific prescription, so nearly all telehealth peptide therapy uses 503A. Within 503A, quality varies enormously, which is why per-batch third-party testing matters so much.
Are compounded peptides FDA-approved?
No. Compounded medications use FDA-approved active ingredients but are not themselves approved as finished products. This applies to every compounded peptide and GLP-1 from every provider.
How do I know which pharmacy my provider uses?
Ask before you order — legitimate providers will tell you. The pharmacy name should also appear on your medication label when it arrives. If neither is true, treat that as a red flag.
Medical disclaimer: Veritide is an independent consumer-research publication, not a healthcare provider or pharmacy. This page is informational and is not medical advice. Compounded medications are not FDA-approved as finished products. Always consult a licensed clinician before starting any peptide or GLP-1 therapy.